Paroxysmal nocturnal hemoglobinuria · 4 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Ravulizumab monotherapy Variant #01 | — | R 59 910 | 14d | — | — | — | — | — |
Eculizumab monotherapy N/A - secondary systemic drug | — | R 0 | — | — | — | — | — | — |
Placebo Partial | — | — | — | ~4.2 mo | ~8.0 mo | — | — | 145 |
Iptacopan monotherapy Variant #02 Partial | — | — | 28d | — | — | — | — | — |
4 of 4 regimens shown